A US technology transfer office required support in evaluating its life science research programs to help direct internal funding towards its most commercially viable projects. Alacrita was commissioned to provide a specialist commercial and technical knowledge base in the pharmaceuticals and life science sector to evaluate a portfolio of patents/IP disclosures from multiple principal investigators. One such project was a novel probiotic delivery system for antimicrobial peptides against infectious disease.
Alacrita works with universities, research institutes, and centers of innovation to help them understand the commercial viability of their programs, bridge the gap between them and the industry, and guide them towards successfully partnering, licensing or spinning-out scientific discoveries. In the current funding environment, tech transfer offices may be forced to carry programs for longer due to the shortage of private money, placing even more importance on optimizing and prioritizing resource allocation.